Advertisement

Quality of Life Research

, Volume 14, Issue 2, pp 453–461 | Cite as

Quality of life related to type 1 Gaucher disease: Spanish experience

  • Pilar Giraldo
  • Victor Solano
  • Juan-Ignacio Pérez-Calvo
  • Manuel Giralt
  • Daniel Rubio-Félix
Article

Abstract

The impact of type 1 Gaucher disease and its therapy on health-related quality of life (QOL) was investigated and the results were compared with a Spanish adult normative group. Patients and Methods: Between January 1998 and December 2002, a prospective clinical QOL trial was conducted by application of a Spanish version of the Health Survey SF-36 questionnaire. Patients receiving ERT (69 cases) filled in the questionnaire two times, prior to starting ERT and after two years under ERT. The patients were stratified by gender and age group. Clinical and X-ray data to assess bone disease were obtained from the Spanish Gaucher Register. Demographic, clinical, genotype and analytical data and the response to therapy were evaluated. Four grades of severity were established according to bone disease (no symptoms=0, moderate bone pain=1, severe bone crisis=2, fracture/necrosis=3). Correlation analysis was made between QOL score and grade of bone disease. Results: Mean age ± SD 33.6 ± 11.7 (range 18–66), M/F ratio 33/36; bone disease: 0 in 27 patients (47.3%), 1 in 11 (19.3%), 2 in 5 (8.8%) and 3 in 14 (24.5%). Physical activity: 11 patients (19.3%) showed severe restriction and 41 patients (71.9%) were only limited for strenuous activities. The mean score for QOL questionnaire was 11.9 ± 10.4 (range 2–46). Correlation between score and bone disease was significant only for 1 and 3 grades (p=0.02). Improvement in self perception of global health was observed ranging from 34.3% before ERT to 91.4% after ERT ( p=0.001). Nevertheless physical activity remained unsatisfactory in 24.5% of patients due mainly to bone sequelae. Comments: Physical activities and bone disease grade 1 and 3 are negatively related to QOL. Nevertheless no correlation was found with bone pain crisis, possibly due to the transitory character of this event. In spite of the improvement induced by ERT, a quarter of patients remained with physical limitations related to bone disease as well as in need of orthopaedic correction of bone sequelae. In order to improve the QOL an accurate evaluation of bone disease to define therapeutic approaches must be considered.

Keywords

Enzyme replacement therapy Type 1 Gaucher diseases Quality of life 

Abbreviations

GD

Gaucher diseases

QOL

Quality of life

SF-36

Short form 36 scales

ERT

enzymatic replacement therapy

GBA

glucocerebrosidase

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beutler, E, Graboski, GA 2001Gaucher diseaseScriver, CRBeaudet, ALSly, WSValle, D eds. The Metabolic and Molecular Basis of Inherited Disease.8McGraw-HillNew York36353668Google Scholar
  2. Alfonso P, Pocoví M. Genética de la enfermedad de Gaucher. Correlación genotipo-fenotipo. En: Giraldo P, Giralt M, Pocovi M, Pérez-Calvo J (eds), Enfermedad de Gaucher. 2ª Ed Zaragoza 2003; pp. 129–150.Google Scholar
  3. Beutler, E, Garber, AM 1994Alglucerase for Gaucher’s disease: Dose, cost and benefits.Pharmacoeconomics5453459Google Scholar
  4. NIH, Technology Assessment Panel on Gaucher Disease 1996Gaucher disease: Current issues in diagnosis and treatment.J Am Med Assoc275548553Google Scholar
  5. American Medical Association. Principles of Outcomes Research. Outcomes Research Resource Guide, 1996/97. American Medical Association 1997.Google Scholar
  6. Clarke, AE, Goldstein, MK, Michelson, D, Garber, AM, Lennert, LA 1997The effect of assessment method and respondent population on utilities elicited for Gaucher disease.Qual Life Res6169184Google Scholar
  7. Damiano, AM, Pastores, GM, Ware, JE 1998The health related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: Results from a retrospective study.Qual Life Res7373386Google Scholar
  8. Masek, BJ, Sims, KB, Bove, CM, Korson, MS, Short, P, Norman, DK 1999Quality of life assessment in adults with type 1 Gaucher disease.Qual life Res8263268Google Scholar
  9. Pastores, GM 2002Quality of life assessment: To measure the health-related burden of Gaucher disease and treatment outcome.Clin Perspect Lysosomal Storage Disorders101619Google Scholar
  10. Giraldo P, Chabás A, Pérez-Calvo J, Epidemiología de la Enfermedad de Gaucher en España. En Giraldo P, Giralt M, Pocovi M, Pérez-Calvo J (eds), Enfermedad de Gaucher. 2ª Ed Zaragoza 2003; 39–56.Google Scholar
  11. Alonso, L, Prieto, J, Antó, JM 1995La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): Un instrumento para la medida de los resultados clínicos.Med Clin (Barc)104771776Google Scholar
  12. Badia X, Salamero M, Alonso J. La medida de la salud. Guía de escalas en español. Barcelona: Edimac, 1999.Google Scholar
  13. Giraldo P, Giralt M, Pocovi M, Pérez-Calvo J. Guía de actuación en pacientes adultos con Enfermedad de Gaucher tipo 1. En: Giraldo P, Giralt M, Pocovi M, Pérez-Calvo J (eds), Enfermedad de Gaucher. 2ª Ed Zaragoza 2003; 269–276.Google Scholar
  14. González, N, Padierna, A, Quintana, JM, Aróstegui, L, Horcajo, MJ 2001Calidad de vida de los pacientes afectados de trastornos de la alimentación.Gac Sanit151824Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Pilar Giraldo
    • 1
  • Victor Solano
    • 2
  • Juan-Ignacio Pérez-Calvo
    • 3
  • Manuel Giralt
    • 1
  • Daniel Rubio-Félix
    • 1
  1. 1.Department of HematologyMiguel Servet University HospitalZaragozaSpain
  2. 2.Department of Epidemiology and Preventive HealthMiguel Servet University HospitalSpain
  3. 3.Department of Internal MedicineClinic University HospitalZaragozaSpain

Personalised recommendations